{"filing":{"accession_number":"0001493152-26-027197","cik":"0000318306","ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315226027197/form8-k.htm"},"events":[{"id":6905,"run_id":6054,"accession_number":"0001493152-26-027197","anchor_item_number":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Abeona disclosed a Pre-IND meeting with the FDA on June 3, 2026 regarding ABO-701, a novel engineered T-cell therapy for prostate cancer, with plans to submit an IND application in 2027. While this represents material regulatory progress for a clinical-stage biopharmaceutical company, it does not fit neatly into the specific event categories (not an earnings release, executive change, M\u0026A activity, impairment, or other defined event type). The disclosure is material because FDA regulatory milestones and clinical development timelines are central to investor assessment of biotech companies' prospects.","company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":4455,"accession_number":"0001493152-26-027197","item_number":null,"item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Abeona disclosed a Pre-IND meeting with the FDA on June 3, 2026 regarding ABO-701, a novel engineered T-cell therapy for prostate cancer, with plans to submit an IND application in 2027. While this represents material regulatory progress for a clinical-stage biopharmaceutical company, it does not fit neatly into the specific event categories (not an earnings release, executive change, M\u0026A activity, impairment, or other defined event type). The disclosure is material because FDA regulatory milestones and clinical development timelines are central to investor assessment of biotech companies' prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:20:32.118838+00:00","company_name":"ABEONA THERAPEUTICS INC.","ticker":"ABEO","filing_date":"2026-06-04"}]}